Lilly Acquires Centessa for Neurology R&D

Jim explains Lilly's $7.8B Centessa acquisition to pursue orexin-based treatments for narcolepsy and mental illness.

Play episode from 45:17

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!